EMR2 (ADGRE2) belongs to the same subfamily as CD97 and shares many similarities, including several EGF domains along its extracellular domain.20 High EMR2 expression has been associated with low-grade gliomas and the mesenchymal subtype of GBM.92 Ivan et al.92 found a correlation between EMR2 and the PI3K pathway, observing that both were upregulated in GBM following therapy with bevacizumab, a monoclonal antibody against VEGF-A occasionally used to treat GBM. Here, ADGRE2 is linked to central nervous system cancer.